Praxis Precision Medicines Inc
For the period ended Dec 31, 2024. Filed Feb 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 28, 2025
PRAX$337.59+1.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts in thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(182,819) | $(123,277) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 358 | 432 |
| Stock-based compensation expense | 41,360 | 24,857 |
| Non-cash operating lease expense | 933 | 837 |
| Amortization of premiums and discounts on marketable securities, net | (5,010) | 47 |
| Non-cash collaboration and license agreement expense | 2,500 | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (8,225) | 6,772 |
| Accounts payable | 6,713 | (8,855) |
| Accrued expenses | 16,110 | (8,497) |
| Operating lease liabilities | (1,126) | (1,005) |
| Deferred revenue | (2,553) | (2,447) |
| Other | 2 | — |
| Net cash used in operating activities | (131,757) | (111,136) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | — | (50) |
| Purchases of marketable securities | (371,519) | — |
| Maturities of marketable securities | 123,025 | 39,000 |
| Net cash (used in) provided by investing activities | (248,494) | 38,950 |
| Cash flows from financing activities: | ||
| Issuance of common stock from follow-on public offering and accompanying pre-funded warrants, net of underwriting discounts, commissions and offering costs | 377,636 | 63,439 |
| Issuance of common stock from collaboration and license agreement | 14,765 | — |
| Proceeds from at-the-market offerings, net of issuance and commission costs | 119,597 | 28,153 |
| Payments of tax withholdings related to vesting of restricted stock units | (308) | (137) |
| Proceeds from exercise of options and employee stock purchase plan purchases | 2,633 | 416 |
| Net cash provided by financing activities | 514,323 | 91,871 |
| Increase in cash, cash equivalents and restricted cash | 134,072 | 19,685 |
| Cash, cash equivalents and restricted cash, beginning of period | 81,716 | 62,031 |
| Cash, cash equivalents and restricted cash, end of period | $215,788 | $81,716 |
| Reconciliation of cash, cash equivalents and restricted cash: | ||
| Cash and cash equivalents | 215,372 | 81,300 |
| Restricted cash | 416 | 416 |
| Total cash, cash equivalents and restricted cash | $215,788 | $81,716 |
| Supplemental disclosures of non-cash activities: | ||
| Issuance costs from at-the-market offerings included in accrued expenses | $238 | $63 |
| Offering costs from follow-on public offering included in accounts payable | $— | $184 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.